Cognizant's $570 mln trade-secret case win against Syntel thrown out on appeal 

<html xmlns=""><head><title>Cognizant's $570 mln trade-secret case win against Syntel thrown out on appeal </title></head><body>

Cognizant previously won $854 mln from rival in software dispute

Court said amount of trade-secret award not justified

By Blake Brittain

(Reuters) -A U.S. appeals court on Thursday vacated a $570 million award Cognizant Technology Solutions Corp CTSH.O had won against rival software provider Atos SE's ATOS.PA Syntel Inc for theft of its trade secrets related to healthcare insurance software.

The New York-based 2nd U.S. Circuit Court of Appeals said Cognizant was not entitled to the damages under the federal trade secret law and ordered a Manhattan federal court to reconsider based on other grounds.

The court, however, affirmed that Syntel was liable for misusing the trade secrets that belonged to Cognizant's TriZetto Healthcare.

A spokesperson for Teaneck, New Jersey-based Cognizant said the company was pleased with the liability ruling and is "evaluating its appeal options" for the damages decision.

Representatives for France-based Atos did not immediately respond to a request for comment.

A Syntel unit first sued Cognizant and TriZetto in 2015, alleging Cognizant's acquisition of TriZetto resulted in a breach of Syntel's contract with TriZetto.

Cognizant countersued Syntel for taking trade secrets related to its Facets software, used by healthcare insurance companies to automate administrative tasks, during its work with TriZetto and using them to develop a competing product.

Cognizant fended off Syntel's claims, and a jury awarded it $854 million in damages against Syntel for misusing its trade secrets in 2020. The district court later cut the award to $570 million.

The 2nd Circuit affirmed Thursday that Syntel was liable for misappropriating more than 100 Cognizant trade secrets. But it took issue with the legal theory that had justified Cognizant's damages.

Cognizant's award under federal trade-secret law was largely based on its estimate that Syntel saved $285 million on research and development for its software by using the secrets, an amount the court doubled in punitive damages. The appeals court said Cognizant did not suffer harm that would justify the "avoided costs" award, such as losing the value of its trade secrets.

"TriZetto's valuable trade secrets are still that—valuable and secret," U.S. Circuit Judge Richard Wesley wrote for a three-judge panel.

Cognizant also won $142 million for its trade secret claims under New York law and $59 million for copyright infringement, which did not factor in to the jury's total damages award. The appeals court told the Manhattan court to reconsider those awards in the wake of the Thursday decision.

The case is Syntel Sterling Best Shores Mauritius Ltd v. TriZetto Group Inc, 2nd U.S. Circuit Court of Appeals, No. 21-1370.

For Syntel: Kannon Shanmugam of Paul Weiss Rifkind Wharton & Garrison

For Cognizant: John O'Quinn of Kirkland & Ellis

Read more:

Cognizant, TriZetto announce $854 million trade secret verdict against Syntel

Cognizant sued by Syntel unit following TriZetto acquisition

Reporting by Blake Brittain in Washington


Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.